169 related articles for article (PubMed ID: 34826154)
1. Anti-CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems.
Barbour M; Wood R; Harte T; Bushell TJ; Jiang HR
Immunology; 2022 Mar; 165(3):312-327. PubMed ID: 34826154
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
5. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
6. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double-negative T cells and newly generated T and B cells.
Haile Y; Adegoke A; Laribi B; Lin J; Anderson CC
Eur J Immunol; 2020 Sep; 50(9):1362-1373. PubMed ID: 32388861
[TBL] [Abstract][Full Text] [Related]
8. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
Demir S; Pitarokoili K; Linker R; Gold R
J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
[TBL] [Abstract][Full Text] [Related]
9. CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis.
Bogie JF; Grajchen E; Wouters E; Broux B; Stinissen P; Van Wijmeersch B; Hendriks JJ
Ther Adv Chronic Dis; 2020; 11():2040622320947378. PubMed ID: 32913622
[TBL] [Abstract][Full Text] [Related]
10. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
[TBL] [Abstract][Full Text] [Related]
11. CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.
Shafiei-Jahani P; Helou DG; Hurrell BP; Galle-Treger L; Howard E; Quach C; Painter JD; Fung M; Lo R; Allayee H; Akbari O
Mucosal Immunol; 2021 Jul; 14(4):899-911. PubMed ID: 33731828
[TBL] [Abstract][Full Text] [Related]
12. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
13. The role of CNS TLR2 activation in mediating innate versus adaptive neuroinflammation.
Luz A; Fainstein N; Einstein O; Ben-Hur T
Exp Neurol; 2015 Nov; 273():234-42. PubMed ID: 26342755
[TBL] [Abstract][Full Text] [Related]
14. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
[TBL] [Abstract][Full Text] [Related]
15. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
16. Sex-Specific Effects of Microglia-Like Cell Engraftment during Experimental Autoimmune Encephalomyelitis.
Han J; Zhu K; Zhou K; Hakim R; Sankavaram SR; Blomgren K; Lund H; Zhang XM; Harris RA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957621
[TBL] [Abstract][Full Text] [Related]
17. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
18. Endurance Exercise Attenuates Established Progressive Experimental Autoimmune Encephalomyelitis and Is Associated with an Amelioration of Innate Immune Responses in NOD Mice.
Schiffmann D; Lampkemeyer V; Lindner M; Fleck AK; Koch K; Eschborn M; Liebmann M; Strecker JK; Minnerup J; Wiendl H; Klotz L
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958787
[TBL] [Abstract][Full Text] [Related]
19. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
20. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
